ISET 2025
1-Year Results From the RESOLV I Trial
03/14/2025
In this video, Marianne Brodmann, MD, from the Medical University of Graz, Austria, provides an overview of her ISET 2025 presentation on the 1-year results of the RESOLV I trial, the first-in-human study to determine the safety and efficacy of the Magnitude bioresorbable drug-eluting scaffold (R3 Vascular) in patients with severe peripheral arterial disease.
Related Content
About Us
Vascular Disease Management™ (VDM), the official media partner of the International Symposium on Endovascular Therapy (ISET) and the Amputation Prevention Symposium (AMP), is a peer-reviewed journal that educates readers on the latest advancements in endovascular treatment strategies.
Learn more about ISET and AMP and register for the events here:
Subscribe Now!
Vascular Disease Management Newsletter




